A phase 3, multicenter, randomized, stratified, placebo-controlled, double-blind, parallel group studyto investigate the efficacy and safety of ATL-962 in obese patients with type 2 diabetes anddyslipidemia.
Phase of Trial: Phase III
Latest Information Update: 20 May 2016
At a glance
- Drugs Cetilistat (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- 22 Dec 2008 Status changed from not yet recruiting to recruiting according to a Takeda media release.
- 11 Mar 2008 New trial record.